METABOLIC DISORDERS
Effect of elcatonin in addition to risedronate for women with osteoporosis and back pain
J Bone Miner Metab. 2015 Jul;33(4):432-945 postmenopausal women with a diagnosis of osteoporosis and chronic back pain were randomized to receive either combined therapy of risedronate and elcatonin, or risedronate therapy alone. The purpose of the study was to determine if there was an additive effect of elcatonin to risedronate therapy with respect to pain and quality of life outcomes over 6 months. Results demonstrated no between-group differences in outcome on either the Roland-Morris questionnaire (RMQ) for low back pain, or the Japanese Osteoporosis Quality of Life Questionnaire (JOQOL). There was also no significant between-group differences in domains of the Short Form 36-Item General Health Survey (SF-36).
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
